At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by private equity firm Nordic Capital.

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced.

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by private equity firm Nordic Capital.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.

(The Hill) – Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...